Robert Schickel

Co-Founder, Chief Executive Officer, NUAgo Therapeutics

Graduation Year: 2009

Thesis: The Characterization of Fas Non-apoptotic Signaling and Identification of miR-200c as a regulator of Fas Signaling

Advisor: Peter Marcus